

<p>93-121261/15      B05 (B07)      TAIH 91.08.30          TAIHO PHARM CO LTD      *JP 05058879-A          91.08.30 91JP-247096 (93.03.09) A61K 9/127, 47/24, 47/28  <b>Liposome prepn. contg. carcinostatic substance - comprises small grain size liposome comprising hydrogenated natural phospholipid, cholesterol and negatively charged lipid</b>  <b>C93-053869</b></p>	B(2-D, 2-M, 2-P1, 4-B3A, 12-G7, 12-M11F)
<p>Prepn. comprises liposome with 100 nm or less mean grain size, consisting of hydrogenated natural phospholipid, cholesterol, and lipid with negative charge.</p> <p>The hydrogenated natural phospholipid is pres. egg yolk lecithin, or soybean lecithin. The lipid with negative charge is dicetyl phosphate or phosphatidic acid. The carcinostatic substance is fluorodeoxy uridine, cytosin arabinoside, mitomycin C, bleomycin daunorubicin, or doxorubicin. The liposome prepn. is in form of injection, or freeze-dried powder.</p> <p>USE/ADVANTAGE - For targetting of cancer.</p> <p>In an example, hydrogenated egg yolk lecithin, cholesterol and dicetyl phosphate (5 : 4 : 1 mol) were dissolved in chloroform (with total lipid of 0.2 mmol), and formed into liposome of lipid. After removal of chloroform, fluorodeoxyuridine (2g)-contg. phosphoric acid buffer (5ml; pH7.4) was added to the liposome, and stirred for 1 hr. with addn. of ultrasonic wave to form liposome suspension contg. SUV liposome with 44.5 +/- 23 nm grain size. (6pp Dwg.No.0/0)</p>	